Osimertinib Mesylate: A Third-Generation EGFR Inhibitor for Advanced Non-Small Cell Lung Cancer
Targeting resistant EGFR mutations for improved NSCLC patient outcomes.
Get a Quote & SampleProduct Core Value
Osimertinib Mesylate
Osimertinib Mesylate is a potent third-generation, covalent, irreversible, and mutation-selective EGFR inhibitor. It is primarily used in the treatment of non-small cell lung cancer (NSCLC) that has developed resistance to first- and second-generation EGFR inhibitors, particularly those harboring the T790M mutation. Its ability to target resistant EGFR mutations significantly benefits patients.
- Investigating Osimertinib Mesylate for other types of cancers is crucial for expanding its therapeutic potential as a broad-spectrum antitumor agent.
- Combination therapy with Osimertinib Mesylate is being explored to enhance treatment efficacy and overcome drug resistance in various cancer types.
- Inhibiting EGFR mutations like T790M effectively halts tumor growth by blocking critical signaling pathways.
- Improved patient outcomes are a direct result of Osimertinib Mesylate's targeted approach, leading to better progression-free and overall survival in NSCLC patients.
Advantages Offered by the Product
Targeted Mutation Inhibition
Osimertinib Mesylate effectively targets specific EGFR mutations, such as the T790M mutation, which is key in overcoming drug resistance in NSCLC.
Enhanced Patient Survival
Demonstrating improved progression-free survival and overall survival, this targeted therapy significantly benefits patients suffering from resistant NSCLC.
Minimized Side Effects
Its mutation-selective properties lead to fewer off-target effects, resulting in reduced potential adverse reactions and improved treatment tolerability for patients.
Key Applications
Non-Small Cell Lung Cancer (NSCLC) Treatment
Osimertinib Mesylate is a critical component in treating NSCLC, especially when resistance to earlier EGFR inhibitors emerges, particularly with the T790M mutation.
Investigational Cancer Therapy
The potential of Osimertinib Mesylate as a broad-spectrum antitumor agent is being actively explored in clinical trials for various other cancer types.
Combination Treatment Strategies
Researchers are examining how to best integrate Osimertinib Mesylate with other treatments to boost efficacy and combat therapeutic resistance.
Research and Development
As a pharmaceutical intermediate, it plays a vital role in the R&D of new oncology drugs and treatment protocols.
Related Technical Articles & Resources
Why Choose Us?
Leverage our expertise and state-of-the-art infrastructure to accelerate your journey from discovery to commercial success.
Global Experience
With 20 years of R&D, manufacturing, and sales experience, we proudly serve clients across 60 countries and regions worldwide.
Advanced Facilities
Our in-house R&D laboratory, pilot platform, and large-scale production workshop are equipped to meet the audit requirements of global customers.
Seamless Scalability
We facilitate a perfect transition from small-scale lab requirements (grams) to full commercialization (hundreds of tons).